The neurokinin-1 receptor in addictive processes

Journal of Pharmacology and Experimental Therapeutics

Volumn 351, Issue 1, 2014, Pages 2-8

  Schank, Jesse R ^a  

^a UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; COCAINE; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; EZLOPITANT; MORPHINE; N [[2 CYCLOPROPOXY 5 (5 TRIFLUOROMETHYL)TETRAZOL 1 YL]BENZYL] 2 PHENYLPIPERIDIN 3 AMINE; NALTREXONE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; OPIATE; SERLOPITANT; SUBSTANCE P; UNCLASSIFIED DRUG;

ALCOHOL CONSUMPTION; ALCOHOLISM; CLINICAL TRIAL (TOPIC); COCAINE DEPENDENCE; DRUG DEPENDENCE; DRUG SEEKING BEHAVIOR; DRUG TARGETING; GENETIC ASSOCIATION; HORMONE ACTION; HUMAN; MENTAL STRESS; NEUROTRANSMISSION; NONHUMAN; OPIATE ADDICTION; REINFORCEMENT; REVIEW; REWARD; ANIMAL; METABOLISM; SUBSTANCE-RELATED DISORDERS;

ANIMALS; CORTICOTROPIN-RELEASING HORMONE; HUMANS; NEUROKININ-1 RECEPTOR ANTAGONISTS; RECEPTORS, NEUROKININ-1; SUBSTANCE P; SUBSTANCE-RELATED DISORDERS;

EID: 84907164744     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.210799     Document Type: Review

References (87)

1. Baek MN, Jung KH, Halder D, Choi MR, Lee BH, Lee BC, Jung MH, Choi IG, Chung MK, and Oh DY, et al. (2010) Artificial microRNA-based neurokinin-1 receptor gene silencing reduces alcohol consumption in mice. Neurosci Lett 475:124-128.
2. Barbier E, Vendruscolo LF, Schlosburg JE, Edwards S, Juergens N, Park PE, Misra KK, Cheng K, Rice KC, and Schank J, et al. (2013) The NK1 receptor antagonist L822429 reduces heroin reinforcement. Neuropsychopharmacology 38:976-984.
3. Blaine S, Claus E, Harlaar N, and Hutchison K (2013) TACR1 genotypes predict fMRI response to alcohol cues and level of alcohol dependence. Alcohol Clin Exp Res 37 (Suppl 1):E125-E130.
4. Borsook D, Upadhyay J, Klimas M, Schwarz AJ, Coimbra A, Baumgartner R, George E, Potter WZ, Large T, and Bleakman D, et al. (2012) Decision-making using fMRI in clinical drug development: revisiting NK-1 receptor antagonists for pain. Drug Discov Today 17:964-973.
5. Cheeseman HJ, Pinnock RD, and Henderson G (1983) Substance P excitation of rat locus coeruleus neurones. Eur J Pharmacol 94:93-99.
6. Chen LW, Wei LC, Liu HL, and Rao ZR (2000) Noradrenergic neurons expressing substance P receptor (NK1) in the locus coeruleus complex: a double immunofluorescence study in the rat. Brain Res 873:155-159.
7. Conley RK, Cumberbatch MJ, Mason GS,Williamson DJ, Harrison T, Locker K, Swain C, Maubach K, O'Donnell R, and Rigby M, et al. (2002) Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity. J Neurosci 22:7730-7736.
8. Duarte FS, Testolin R, and De Lima TC (2004) Further evidence on the anxiogeniclike effect of substance P evaluated in the elevated plus-maze in rats. Behav Brain Res 154:501-510.
9. Dunn AJ, Swiergiel AH, and Palamarchouk V (2004) Brain circuits involved in corticotropin-releasing factor-norepinephrine interactions during stress. Ann N Y Acad Sci 1018:25-34.
10. Ebner K, Muigg P, Singewald G, and Singewald N (2008a) Substance P in stress and anxiety: NK-1 receptor antagonism interacts with key brain areas of the stress circuitry. Ann N Y Acad Sci 1144:61-73.
11. Ebner K, Rupniak NM, Saria A, and Singewald N (2004) Substance P in the medial amygdala: emotional stress-sensitive release and modulation of anxiety-related behavior in rats. Proc Natl Acad Sci USA 101:4280-4285.
12. Ebner K and Singewald N (2006) The role of substance P in stress and anxiety responses. Amino Acids 31:251-272.
13. Ebner K, Singewald GM, Whittle N, Ferraguti F, and Singewald N (2008b) Neurokinin 1 receptor antagonism promotes active stress coping via enhanced septal 5- HT transmission. Neuropsychopharmacology 33:1929-1941.
14. Erb S, Hitchcott PK, Rajabi H, Mueller D, Shaham Y, and Stewart J (2000) Alpha-2 adrenergic receptor agonists block stress-induced reinstatement of cocaine seeking. Neuropsychopharmacology 23:138-150.
15. Gadd CA, Murtra P, De Felipe C, and Hunt SP (2003) Neurokinin-1 receptorexpressing neurons in the amygdala modulate morphine reward and anxiety behaviors in the mouse. J Neurosci 23:8271-8280.
16. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, and Brandt JE, et al. (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319:1536-1539.
17. Gilpin NW and Koob GF (2010) Effects of b-adrenoceptor antagonists on alcohol drinking by alcohol-dependent rats. Psychopharmacology (Berl) 212:431-439.
18. Gobbi G, Cassano T, Radja F, Morgese MG, Cuomo V, Santarelli L, Hen R, and Blier P (2007) Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin function. Eur Neuropsychopharmacol 17:328-338.
19. Guiard BP, Guilloux JP, Reperant C, Hunt SP, Toth M, and Gardier AM (2007) Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin release in the mouse frontal cortex. Mol Pharmacol 72: 1411-1418.
20. Guyenet PG and Aghajanian GK (1977) Excitation of neurons in the nucleus locus coeruleus by substance P and related peptides. Brain Res 136:178-184.
21. Hamke M, Herpfer I, Lieb K, Wandelt C, and Fiebich BL (2006) Substance P induces expression of the corticotropin-releasing factor receptor 1 by activation of the neurokinin-1 receptor. Brain Res 1102:135-144.
22. Hansson AC, Cippitelli A, Sommer WH, Fedeli A, Björk K, Soverchia L, Terasmaa A, Massi M, Heilig M, and Ciccocioppo R (2006) Variation at the rat Crhr1 locus and sensitivity to relapse into alcohol seeking induced by environmental stress. Proc Natl Acad Sci USA 103:15236-15241.
23. Heilig M and Koob GF (2007) A key role for corticotropin-releasing factor in alcohol dependence. Trends Neurosci 30:399-406.
24. Hutson PH, Patel S, Jay MT, and Barton CL (2004) Stress-induced increase of cortical dopamine metabolism: attenuation by a tachykinin NK1 receptor antagonist. Eur J Pharmacol 484:57-64.
25. Kawano H and Masuko S (1992) Met-enkephalin-Arg6-Gly7-Leu8- and substance P-containing projections from the nucleus preopticus medianus to the paraventricular hypothalamic nucleus. Neurosci Lett 148:211-215.
26. Keller M, Montgomery S, Ball W, Morrison M, Snavely D, Liu G, Hargreaves R, Hietala J, Lines C, and Beebe K, et al. (2006) Lack of efficacy of the substance p (neurokinin1 receptor) antagonist aprepitant in the treatment of major depressive disorder. Biol Psychiatry 59:216-223.
27. Koob GF (2003) Neuroadaptive mechanisms of addiction: studies on the extended amygdala. Eur Neuropsychopharmacol 13:442-452.
28. Koob GF (2009a) Brain stress systems in the amygdala and addiction. Brain Res 1293:61-75.
29. Koob GF (2009b) Neurobiological substrates for the dark side of compulsivity in addiction. Neuropharmacology 56 (Suppl 1):18-31.
30. Koob GF (2010) The role of CRF and CRF-related peptides in the dark side of addiction. Brain Res 1314:3-14.
31. Koob GF and Le Moal M (2008) Review. Neurobiological mechanisms for opponent motivational processes in addiction. Philos Trans R Soc Lond B Biol Sci 363: 3113-3123.
32. Koob GF and Zorrilla EP (2010) Neurobiological mechanisms of addiction: focus on corticotropin-releasing factor. Curr Opin Investig Drugs 11:63-71.
33. Kraft M, Ahluwahlia S, and Angulo JA (2001a) Neurokinin-1 receptor antagonists block acute cocaine-induced horizontal locomotion. Ann N Y Acad Sci 937:132-139.
34. Kraft M, Noailles P, and Angulo JA (2001b) Substance P modulates cocaine-evoked dopamine overflow in the striatum of the rat brain. Ann N Y Acad Sci 937:121-131.
35. Kramer MS, Cutler N, Feighner J, Shrivastava R, Carman J, Sramek JJ, Reines SA, Liu G, Snavely D, and Wyatt-Knowles E, et al. (1998) Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 281: 1640-1645.
36. Leri F, Flores J, Rodaros D, and Stewart J (2002) Blockade of stress-induced but not cocaine-induced reinstatement by infusion of noradrenergic antagonists into the bed nucleus of the stria terminalis or the central nucleus of the amygdala. J Neurosci 22:5713-5718.
37. Loonam TM, Noailles PA, Yu J, Zhu JP, and Angulo JA (2003) Substance P and cholecystokinin regulate neurochemical responses to cocaine and methamphetamine in the striatum. Life Sci 73:727-739.
38. Ma QP and Bleasdale C (2002) Modulation of brain stem monoamines and gammaaminobutyric acid by NK1 receptors in rats. Neuroreport 13:1809-1812.
39. Mantsch JR, Weyer A, Vranjkovic O, Beyer CE, Baker DA, and Caretta H (2010) Involvement of noradrenergic neurotransmission in the stress- but not cocaineinduced reinstatement of extinguished cocaine-induced conditioned place preference in mice: role for beta-2 adrenergic receptors. Neuropsychopharmacology 35: 2165-2178.
40. Mantyh PW, Hunt SP, and Maggio JE (1984) Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res 307:147-165.
41. Maubach KA, Martin K, Chicchi G, Harrison T, Wheeldon A, Swain CJ, Cumberbatch MJ, Rupniak NM, and Seabrook GR (2002) Chronic substance P (NK1) receptor antagonist and conventional antidepressant treatment increases burst firing of monoamine neurones in the locus coeruleus. Neuroscience 109:609-617.
42. Michelson D, Hargreaves R, Alexander R, Ceesay P, Hietala J, Lines C, and Reines S (2013) Lack of efficacy of L-759274, a novel neurokinin 1 (substance P) receptor antagonist, for the treatment of generalized anxiety disorder. Int J Neuropsychopharmacol 16:1-11.
43. Millan MJ, Lejeune F, De Nanteuil G, and Gobert A (2001) Selective blockade of neurokinin (NK)(1) receptors facilitates the activity of adrenergic pathways projecting to frontal cortex and dorsal hippocampus in rats. J Neurochem 76: 1949-1954.
44. Murtra P, Sheasby AM, Hunt SP, and De Felipe C (2000) Rewarding effects of opiates are absent in mice lacking the receptor for substance P. Nature 405:180-183.
45. Noailles PA and Angulo JA (2002) Neurokinin receptors modulate the neurochemical actions of cocaine. Ann N Y Acad Sci 965:267-273.
46. Pennefather JN, Lecci A, Candenas ML, Patak E, Pinto FM, and Maggi CA (2004) Tachykinins and tachykinin receptors: a growing family. Life Sci 74:1445-1463.
47. Placenza FM, Fletcher PJ, Rotzinger S, and Vaccarino FJ (2004) Infusion of the substance P analogue, DiMe-C7, into the ventral tegmental area induces reinstatement of cocaine-seeking behaviour in rats. Psychopharmacology (Berl) 177:111-120.
48. Placenza FM, Fletcher PJ, Vaccarino FJ, and Erb S (2006) Effects of central neurokinin-1 receptor antagonism on cocaine- and opiate-induced locomotor activity and selfadministration behaviour in rats. Pharmacol Biochem Behav 84:94-101.
49. Placenza FM, Vaccarino FJ, Fletcher PJ, and Erb S (2005) Activation of central neurokinin-1 receptors induces reinstatement of cocaine-seeking behavior. Neurosci Lett 390:42-47.
50. Quartara L, Altamura M, Evangelista S, and Maggi CA (2009) Tachykinin receptor antagonists in clinical trials. Expert Opin Investig Drugs 18:1843-1864.
51. Quirion R, Shults CW, Moody TW, Pert CB, Chase TN, and O'Donohue TL (1983) Autoradiographic distribution of substance P receptors in rat central nervous system. Nature 303:714-716.
52. Ratti E, Bellew K, Bettica P, Bryson H, Zamuner S, Archer G, Squassante L, Bye A, Trist D, and Krishnan KR, et al. (2011) Results from 2 randomized, double-blind, placebo-controlled studies of the novel NK1 receptor antagonist casopitant in patients with major depressive disorder. J Clin Psychopharmacol 31:727-733.
53. Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G, Gomeni R, Lawson E, Lopez M, and Millns H, et al. (2013) Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol 27:424-434.
54. Renoldi G and Invernizzi RW (2006) Blockade of tachykinin NK1 receptors attenuates stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial prefrontal cortex. J Neurosci Res 84:961-968.
55. Ripley TL, Gadd CA, De Felipe C, Hunt SP, and Stephens DN (2002) Lack of selfadministration and behavioural sensitisation to morphine, but not cocaine, in mice lacking NK1 receptors. Neuropharmacology 43:1258-1268.
56. Robinson JE, Fish EW, Krouse MC, Thorsell A, Heilig M, and Malanga CJ (2012) Potentiation of brain stimulation reward by morphine: effects of neurokinin-1 receptor antagonism. Psychopharmacology (Berl) 220:215-224.
57. Rotzinger S, Lovejoy DA, and Tan LA (2010) Behavioral effects of neuropeptides in rodent models of depression and anxiety. Peptides 31:736-756.
58. Santarelli L, Gobbi G, Debs PC, Sibille ET, Blier P, Hen R, and Heath MJ (2001) Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function. Proc Natl Acad Sci USA 98:1912-1917.
59. Sarnyai Z, Shaham Y, and Heinrichs SC (2001) The role of corticotropin-releasing factor in drug addiction. Pharmacol Rev 53:209-243.
60. Schank JR, King CE, Sun H, Cheng K, Rice KC, Heilig M, Weinshenker D, and Schroeder JP (2014) The role of the neurokinin-1 receptor in stress-induced reinstatement of alcohol and cocaine seeking. Neuropsychopharmacology 39: 1093-1101.
61. Schank JR, Pickens CL, Rowe KE, Cheng K, Thorsell A, Rice KC, Shaham Y, and Heilig M (2011) Stress-induced reinstatement of alcohol-seeking in rats is selectively suppressed by the neurokinin 1 (NK1) antagonist L822429. Psychopharmacology (Berl) 218:111-119.
62. Schank JR, Tapocik JD, Barbier E, Damadzic R, Eskay RL, Sun H, Rowe KE, King CE, Yao M, and Flanigan ME, et al. (2013) Tacr1 gene variation and neurokinin 1 receptor expression is associated with antagonist efficacy in genetically selected alcohol-preferring rats. Biol Psychiatry 73:774-781.
63. Seneviratne C, Ait-Daoud N, Ma JZ, Chen G, Johnson BA, and Li MD (2009) Susceptibility locus in neurokinin-1 receptor gene associated with alcohol dependence. Neuropsychopharmacology 34:2442-2449.
64. Shaham Y, Highfield D, Delfs J, Leung S, and Stewart J (2000) Clonidine blocks stress-induced reinstatement of heroin seeking in rats: an effect independent of locus coeruleus noradrenergic neurons. Eur J Neurosci 12:292-302.
65. Shalev U, Erb S, and Shaham Y (2010) Role of CRF and other neuropeptides in stress-induced reinstatement of drug seeking. Brain Res 1314:15-28.
66. Shults CW, Quirion R, Chronwall B, Chase TN, and O'Donohue TL (1984) A comparison of the anatomical distribution of substance P and substance P receptors in the rat central nervous system. Peptides 5:1097-1128.
67. Singewald N, Chicchi GG, Thurner CC, Tsao KL, Spetea M, Schmidhammer H, Sreepathi HK, Ferraguti F, Singewald GM, and Ebner K (2008) Modulation of basal and stress-induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-822429. J Neurochem 106:2476-2488.
68. Snider RM, Constantine JW, Lowe JA, 3rd, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, and Spencer RW, et al. (1991) A potent nonpeptide antagonist of the substance P (NK1) receptor. Science 251:435-437.
69. Specio SE, Wee S, O'Dell LE, Boutrel B, Zorrilla EP, and Koob GF (2008) CRF(1) receptor antagonists attenuate escalated cocaine self-administration in rats. Psychopharmacology (Berl) 196:473-482.
70. Steensland P, Simms JA, Nielsen CK, Holgate J, Bito-Onon JJ, and Bartlett SE (2010) The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol. PLoS ONE 5:e12527.
71. Tauscher J, Kielbasa W, Iyengar S, Vandenhende F, Peng X, Mozley D, Gehlert DR, and Marek G (2010) Development of the 2nd generation neurokinin-1 receptor antagonist LY686017 for social anxiety disorder. Eur Neuropsychopharmacol 20: 80-87.
72. Teixeira RM, Santos AR, Ribeiro SJ, Calixto JB, Rae GA, and De Lima TC (1996) Effects of central administration of tachykinin receptor agonists and antagonists on plus-maze behavior in mice. Eur J Pharmacol 311:7-14.
73. Thorsell A, Schank JR, Singley E, Hunt SP, and Heilig M (2010) Neurokinin-1 receptors (NK1R:s), alcohol consumption, and alcohol reward in mice. Psychopharmacology (Berl) 209:103-111.
74. Trist DG, Ratti E, and Bye A (2013) Why receptor reserve matters for neurokinin1 (NK1) receptor antagonists. J Recept Signal Transduct Res 33:333-337.
75. Valentino RJ, Bey V, Pernar L, and Commons KG (2003) Substance P acts through local circuits within the rat dorsal raphe nucleus to alter serotonergic neuronal activity. J Neurosci 23:7155-7159.
76. Valentino RJ and Commons KG (2005) Peptides that fine-tune the serotonin system. Neuropeptides 39:1-8.
77. Valentino RJ, Lucki I, and Van Bockstaele E (2010) Corticotropin-releasing factor in the dorsal raphe nucleus: linking stress coping and addiction. Brain Res 1314: 29-37.
78. Vranjkovic O, Hang S, Baker DA, and Mantsch JR (2012) b-adrenergic receptor mediation of stress-induced reinstatement of extinguished cocaine-induced conditioned place preference in mice: roles for b1 and b2 adrenergic receptors. J Pharmacol Exp Ther 342:541-551.
79. Walsh SL, Heilig M, Nuzzo PA, Henderson P, and Lofwall MR (2013) Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol 18:332-343.
80. Wan Q, Douglas SD, Wang X, Kolson DL, O'Donnell LA, and Ho WZ (2006) Morphine upregulates functional expression of neurokinin-1 receptor in neurons. J Neurosci Res 84:1588-1596.
81. Wee S, Mandyam CD, Lekic DM, and Koob GF (2008) Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol 18:303-311.
82. Wee S, Orio L, Ghirmai S, Cashman JR, and Koob GF (2009) Inhibition of kappa opioid receptors attenuated increased cocaine intake in rats with extended access to cocaine. Psychopharmacology (Berl) 205:565-575.
83. Womack MD and Barrett-Jolley R (2007) Activation of paraventricular nucleus neurones by the dorsomedial hypothalamus via a tachykinin pathway in rats. Exp Physiol 92:671-676.
84. Womack MD, Morris R, Gent TC, and Barrett-Jolley R (2007) Substance P targets sympathetic control neurons in the paraventricular nucleus. Circ Res 100: 1650-1658.
85. Yip J and Chahl LA (2000) Localization of tachykinin receptors and Fos-like immunoreactivity induced by substance P in guinea-pig brain. Clin Exp Pharmacol Physiol 27:943-946.
86. Yu YJ, Arttamangkul S, Evans CJ, Williams JT, and von Zastrow M (2009) Neurokinin 1 receptors regulate morphine-induced endocytosis and desensitization of mu-opioid receptors in CNS neurons. J Neurosci 29:222-233.
87. Zamuner S, Rabiner EA, Fernandes SA, Bani M, Gunn RN, Gomeni R, Ratti E, and Cunningham VJ (2012) A pharmacokinetic PET study of NK1 receptor occupancy. Eur J Nucl Med Mol Imaging 39:226-235.